Process Economic Drivers in Industrial Monoclonal Antibody Manufacture

Process Scale Purification of Antibodies

Volumn , Issue , 2008, Pages 239-261

  Farid, Suzanne S ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Cost effective mAb platform technologies; Overall process economic drivers; Process economic drivers in antibody manufacture

Indexed keywords

EID: 84890735667     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470444894.ch12     Document Type: Chapter

References (77)

1. Reichert, J.M., Rosensweig, C.J., Faden, L.B., Dewitz, M.C. (2005). M onoclonal antibodies successes in the clinic. Nature Biotechnology 23, 1073-1078.
2. Gottschalk, U. (2006). The renaissance of protein purification. BioPharm International 19 (6), S8-9.
3. Datar, R.V., Cartwright, T., Rosen, C. (1993). Process economics of animal cell and bacterial fermentations: a case study analysis of tPA. Bio/Technology 11, 349-357.
4. Sadana, A., Beelaram, A.M. (1994). Efficiency and economics of bioseparation: Some case studies. Bioseparation 4, 221-235.
5. Clemento, A. (1999). New and integrated approaches to successful accelerated drug development. Drug Information Journal 33, 699-710.
6. Mitchell, P. (2005). Next-generation monoclonals less profitable than trailblazers? Nature Biotechnology 23, 906.
7. Wheelwright, S.M. (1991). Protein Purification: Design and Scale-Up of Downstream Processing. Hanser, New York, NY.
8. Farid, S.S., Washbrook, J., Titchener-Hooker, N.J. (2005). Decision-support tool for assessing bio-manufacturing strategies under uncertainty: stainless steel versus disposable equipment for clinical trial material preparation. Biotechnology Progress 21, 486-497.
9. Kamarck, M.E. (2006). Building biomanufacturing capacity - The chapter and verse. Nature Biotechnology 24, 503-505.
10. Kelley, B. (2007). Very large scale monoclonal antibody purification: The case for conventional unit operations. Biotechnology Progress 23, 995-1008.
11. Jagschies, G., O' Hara, A. (2007). Debunking downstream bottleneck myth. Genetic Engineering News 27, 3.
12. Thiel, K.A. (2004). Biomanufacturing, from bust to boom to bubble? Nature Biotechnology 22, 1365-1372.
13. Walsh, G. (1998). Biopharmaceuticals: Biochemistry and Biotechnology. John Wiley and Sons, Chichester.
14. Ginsberg, P.L., Bhatia, S., McMinn, R.L. (2002). The Road Ahead for Biologics Manufacturing. Bancorp Piper Jaffray, New York, NY.
15. Savage, C. (2000). Scaleup and bioproduction. Genetic Engineering News 20, 1, 65, 80.
16. Rajapakse, A., T itchener-Hooker, N.J., Farid, S.S. (2006). Integrated approach to improving the value potential of biopharmaceutical R & D portfolios while mitigating risk. Journal of Chemical Technology and Biotechnology 81, 1705-1714.
17. Low, D., O' Leary, R., Pujar, N.S. (2007). Future of antibody purification. Journal of Chromatography B 848, 48-63.
18. Torphy, T.J. (2002). Monoclonal antibodies: Boundless potential, daunting challenges . Current Opinion in Biotechnology 13, 589-591.
19. Farid, S.S. (2007). Process economics of industrial monoclonal antibody manufacture . Journal of Chromatography B 848, 8-18.
20. Remer, D.S., Idrovo, J.H. (1991). Cost-estimating factors for biopharmaceutical process equipment. BioPharm October, 36-42.
21. Werner, R.G. (1998). Identification and development of new biopharmaceuticals. Drug Research 48, 523-540.
22. Coopers and Lybrand (1997). Pharmaceuticals: Creating Value by Transforming the Cost Base - Our Approach. Company publication.
23. Reisman, H. (1999). Economics. In Flickinger, M.C., Drew, S.W. (eds.) Encyclopaedia of Bioprocess Technology: Fermentation, Biocatalysis and Bioseparation, Vol. 2, pp. 863-882. Wiley, New York, NY.
24. Moscho, A., Hodits, R.A., Janus, F., Leiter, J.M.E. (2000). Deals that make sense. Nature Biotechnology 18, 719-722.
25. Kelley, B.D. (2001). Bioprocessing of therapeutic proteins. Current Opinion in Biotechnology 12, 173-174.
26. Mullen, J. (2000). The position of biopharmaceuticals in the future. Presentation at IBC' s Production and Economics of Biopharmaceuticals - Transcending the Limits of Manufacturing Medicines, La Jolla, CA.
27. Chadd, H.E., Chamow, S.C. (2001). Therapeutic antibody expression technology. Current Opinion in Biotechnology 12, 188-194.
28. Farid, S. (2001). A decision-support tool for simulating the process and business perspectives of biopharmaceutical manufacture. PhD Thesis, University of London.
29. Lim, A.C., Zhou, Y., Washbrook, J., Sinclair, A., Fish, B., Francis, R., Titchener - Hooker, N.J., Farid, S.S. (2005). Application of a decision-support tool to assess pooling strategies in perfusion culture processes under uncertainty. Biotechnology Progress 21, 1231-1242.
30. Lim, A.C., Washbrook, J., Titchener-Hooker, N.J., Farid, S.S. (2006). A computer - aided approach to compare the production economics of fed-batch versus perfusion culture. Biotechnology and Bioengineering 93, 687-697.
31. Farid, S., Novais, J.L., Karri, S., Washbrook, J., Titchener-Hooker, N.J. (2000). A tool for modelling strategic decisions in cell culture manufacturing. Biotechnology Progress 16, 829-836.
32. Pugh, G. (1998). Cell culture manufacturing: an economic perspective from a contract manufacturer' s viewpoint. Presentation at the US Biotechnology Symposium, Washington, DC.
33. Werner, R.G. (2004). Economic aspects of commercial manufacture of biopharmaceuticals . Journal of Biotechnology 113, 171-182.
34. Farid, S.S. (2006). Established bioprocesses for producing antibodies as a basis for future planning. Advances in Biochemical Engineering/Biotechnology 101, 1-42.
35. Sommerfeld, S., Strube, J. (2005). Challenges in biotechnology production - Generic processes and process optimization for monoclonal antibodies. Chemical Engineering and Processing 44, 1123-1137.
36. Brown, M.E., Renner, G., Field, R.P., Hassell, T. (1992). Process development for the production of recombinant antibodies using the glutamine synthetase (GS) system. Cytotechnology 9, 231-236.
37. Birch, J.R., Bonnerjea, J., Flatman, S., Vranch S. (1995). Production of monoclonal antibodies. In Birch, J.R., Lennox, E.S. (eds.) M onoclonal Antibodies: Principles and Application, Wiley-Liss, Inc., New York, NY, pp. 231-265.
38. Bibila, T.A., Robinson, D.R. (1995). In pursuit of the optimal fed-batch process for monoclonal antibody production. Biotechnology Progress 11, 1-13.
39. Wurm, F.M. (2004). Production of recombinant protein therapeutics in cultivated mammalian cells. Nature Biotechnology 22, 1393-1398.
40. Werner, R.G. (2005). The development and production of biopharmaceuticals: Technological and economic success factors. BioProcess International 3 (9), S6-15.
41. Birch, J.R., Racher, A.J. (2006). A ntibody production. A dvanced Drug Delivery Reviews 58, 671-685.
42. Young, M.W., Okita, W.B., Brown, E.M., Curling, J.M (1997). Production of biopharmaceutical proteins in the milk of transgenic dairy animals. BioPharm 10, 34-38.
43. Khoudi, H., Laberge, S., Ferullo, J.-M., Bazin, R., Darveau, A., Castonguay, Y., Allard, G., Lemieux, R., Vezina, L.-P. (1999). Production of a diagnostic monoclonal antibody in perennial alfalfa plants. Biotechnology and Bioengineering 64, 135-143.
44. Sinclair, P.A., Ransohoff, T., Latham, P. (2000). Financial model for production of monoclonal antibodies using transgenic chicken. Presentation at IBC' s Production and Economics of Biopharmaceuticals, La Jolla, CA.
45. Mison, D., Curling, J. (2000). The industrial production costs of recombinant therapeutic proteins expressed in transgenic corn. BioPharm 13, 48-54.
46. Miller, J. (2003). Outsourcing outlook: Signs of change. BioPharm International 16, 32-25.
47. Li, H., Sethuraman, N., Stadheim, T.A., Zha, D., Prinz, B., Ballew, N., Bobrowicz, P., Choi, B.K., Cook, W.J., Cukan, M., Houston-Cummings, N.R., Davidson, R., Gong, B., Hamilton, S.R., Hoopes, J.P., Jiang, Y., Kim, N., Mansfield, R., Nett, J.H., Rios, S., Strawbridge, R., Wildt, S., Gerngross, T.U. (2006). Optimization of humanized IgGs in glycoengineered Pichia pastoris. Nature Biotechnology 24, 210-215.
48. Li, F., Zhou, J.X., Yang, X., Tressel, T., Lee, B. (2005). Current therapeutic antibody production and process optimization. BioProcessing Journal 4, 1-8.
49. Dowd, C., van Reis, R. (2001). Cost reduction strategies in recovery process design. Presentation at IBC' s 4th International Conference on Production and Economics of Biopharmaceuticals, San Diego, CA.
50. Ultee, M.E., Rea, D.W. (1999). Antibody purification. In Flickinger, M.C., Drew S. W. (eds.) Encyclopaedia of Bioprocess Technology: Fermentation, Biocatalysis and Bioseparation, Vol. 1, Wiley, New York, NY, pp. 179-191.
51. Carson, K.L. (2005). Flexibility - The guiding principle for antibody manufacturing. Nature Biotechnology 23, 1054-1058.
52. Watler, P.K. (2001). Cost and capacity comparison of transgenics and cell culture production systems. Presentation at IBC' s 4th International Conference on Production and Economics of Biopharmaceuticals, San Diego, CA.
53. Curbelo, D.R., Garke, G., Guilarte, R.C., Anspach, F.B., Deckwer, W.-D. (2003). Cost comparison of protein capture from cultivation broths by expanded and packed bed adsorption. Engineering in Life Sciences 3, 406-415.
54. Mustafa, M.A., Washbrook, J., Lim, A.C., Zhou, Y., Titchener-Hooker, N.J., Morton, P., Berezenko, S., Farid, S.S. (2005). A software tool to assist business- process decision making in the biopharmaceutical industry. Biotechnology Progress 20, 1096-1102.
55. Blank, G.S., Zapata, G., Fahrner, R., Milton, M., Yedinak, C., Knudsen, H., Schmelzer, C. (2001). Expanded bed adsorption in the purification of monoclonal antibodies: a comparison of process alternatives. Bioseparation 10, 65-71.
56. Mahadevan, M.D. (2003). Bioreactor process selection for large-scale manufacture of monoclonal antibodies - Tradeoffs and recommendations. Bioprocessing Journal 2, 25-31.
57. Farid, S.S., Washbrook, J., Titchener-Hooker, N.J. (2005). Combining multiple quantitative and qualitative goals when assessing biomanufacturing strategies under uncertainty. Biotechnology Progress 21, 1183-1191.
58. Hodge, G. (2004). Disposable components enable a new approach to biopharmaceutical manufacturing. BioPharm International 17, 38-49.
59. Lewis-Sandy, D. (2002). Optimising consumables reuse for therapeutic protein production. Presentation at IBC' s 5th International Conference on Production and Economics of Biopharmaceuticals, San Diego, CA.
60. Rathore, A.S., Latham, P., Levine, H., Curling, J., Kaltenbrunner, O. (2004). Costing issues in the production of biopharmaceuticals. BioPharm International 17, 12-17.
61. Jagschies, G., Gr ö nberg, A., Bj ö rkman, T., Lacki, K., Johansson, H.J. (2006). Technical and economical evaluation of downstream processing options for monoclonal antibody (Mab) production. BioPharm International 19, 23-26.
62. Przybycien, T.M., Pujar, N.S., Steele, L.M. (2004). Alternative bioseparation operations: Life beyond packed-bed chromatography. Current Opinion in Biotechnology 15, 469-478.
63. Follman, D.K., Fahrner, R.L. (2004). Factorial screening of antibody purification processes using three chromatography steps without protein A. Journal of Chromatography A 1024, 79-85.
64. Ghose, S., Hubbard, B., Cramer, S.M. (2006). Evaluation and comparison of alternatives to Protein A chromatography: Mimetic and hydrophobic charge induction chromatographic stationary phases. Journal of Chromatography A 122, 144-152.
65. Aldington, S., Bonnerjea, J. (2007). Scale-up of monoclonal antibody purification processes. Journal of Chromatography B 848, 64-78.
66. Zhou, J., Tressel, T. (2006). Basic concepts in Q membrane chromatography for large-scale antibody production. Biotechnology Progress 22, 341-349.
67. Warner, W.M., Nochumson, S. (2003). Rethinking the economics of chromatography . BioPharm International 16, 58-60.
68. Sinclair, A., Monge, M. (2002). Quantitative economic evaluation of single use disposables in bioprocessing. Pharmaceutical Engineering 22, 20-34.
69. Sinclair, A., Monge, M. (2005). Concept facility based on single-use systems part 2. BioProcess International 3 (9), S51-55.
70. Shukla, A.A., Hubbard, B., Tressel, T., Guhan, S., Low, D. (2007). Downstream processing of monoclonal antibodies - Application of platform approaches. Journal of Chromatography B 848, 28-39.
71. Smith, M. (2004). An evaluation of Protein A and non-Protein A methods for the recovery of monoclonal antibodies and considerations for process scale-up. Presentation at Scaling-up of Biopharmaceutical Products, Amsterdam, the Netherlands.
72. Sofer, G., Chirica, L.C. (2006). Improving productivity in downstream processing. BioPharm International 19, 30-35.
73. Davies, J., Smith, M., Bonnerjea, J. (2004). The infl uence of scale of operation on purification process design. Presentation at the 154th Society for General Microbiology Meeting, Bath, UK.
74. Th ö mmes, J., Etzel, M. (2007). Alternatives to chromatographic separations. Biotechnology Progress 23, 42-45.
75. Knudsen, H., Fahrner, R., Xu, Y., Norling, L., Blank, G. (2001). Membrane ion - exchange chromatography for process-scale antibody purification. Journal of Chromatography A 907, 145-154.
76. Boi, C. (2007). Membrane adsorbers as purification tools for monoclonal antibody purification. Journal of Chromatography B 848, 19-27.
77. Lim, J.A.C., Sinclair, A., Kim, D.S., Gottschalk, U. (2007). Economic benefits of single use membrane chromatography in polishing: A cost of goods model. BioProcess International 5, 60-64.